Expediting drug approval

In recent years, FDA has made great advances in the review of new drugs. From 2012 to 2015, FDA approved a record number of marketing applications for novel drugs, averaging 38 approved products per year. In 2016, FDA approved only 22 novel drugs but the percentage of applications leveraging an expedited program was at its highest.

Spotlight

Antares Pharma Inc.

Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective medicines.

OTHER WHITEPAPERS
news image

Getting serious about serialization: A comprehensive look at thelegislation shaping U.S. pharmaceutical supply chains

whitePaper | October 7, 2022

The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.

Read More
news image

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More
news image

THE PHARMACEUTICAL INDUSTRY AND GLOBAL HEALTH

whitePaper | January 31, 2022

COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was first identified in December 2019.

Read More
news image

Why Deck 7

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

Read More
news image

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Read More
news image

Understanding the true cost of transparency reporting

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

Read More

Spotlight

Antares Pharma Inc.

Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective medicines.

Events